



CME Session 2

Neuroimaging Committee in Collaboration with EAN

Sunday, October 18, 09:45–11:15

Session Title

Assessment, Staging and Monitoring of Alzheimer's Disease Neuropathological Changes in the Era of Disease-Modifying Therapies with PET

Chairpersons

Valentina Garibotto (Geneva, Switzerland)

Matthias Brendel (Munich, Germany)

Programme

- | | |
|-------------|--|
| 09:45–10:10 | Lyduine E. Collij (Lund, Sweden): Treatment Stratification and Monitoring of Anti-Amyloid Treatment with Quantitative Amyloid PET |
| 10:10–10:30 | Nicolai Franzmeier (Munich, Germany): Specific Staging of Alzheimer's Disease Neuropathology with Tau PET |
| 10:30–10:50 | Cecilia Boccalini (Geneva, Switzerland): Assessment of Neurodegeneration Patterns in Alzheimer's Disease and Related Disorders |
| 10:50–11:15 | Federica Agosta (Milan, Italy): Real World Experience with PET Imaging for Inclusion and Monitoring of Anti-Amyloid Treatment |

Educational Objectives

1. Understand the value of amyloid PET assessment for stratification and monitoring of anti-amyloid treatment
2. Understand the value of tau PET for staging of Alzheimer's disease
3. Recognise the options of molecular imaging for the assessment of neurodegeneration

Summary

The advent of disease-modifying therapies (DMTs), particularly anti-amyloid agents, has fundamentally transformed the clinical management of Alzheimer's disease (AD). In this new therapeutic era, molecular imaging—especially positron emission tomography (PET)—plays a central role in patient stratification, disease staging, and longitudinal treatment monitoring. This CME session provides a comprehensive overview of state-of-the-art PET imaging approaches to assess Alzheimer's disease neuropathological changes in vivo, integrating quantitative amyloid PET, tau PET-based staging, and imaging markers of neurodegeneration. The session covers amyloid PET for treatment stratification and monitoring, tau PET as a staging tool reflecting the topographical progression of tau pathology, and molecular imaging approaches to assess neurodegeneration patterns in Alzheimer's disease and related disorders. Finally, real-world experience with PET imaging for patient inclusion and monitoring of anti-amyloid therapy is presented.

Key Words

Amyloid; Tau; Neurodegeneration; TRAC; Anti-Amyloid Treatment